Latest news with #JustinLee
Korea Herald
23-06-2025
- Business
- Korea Herald
Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research
SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs. The new entity provides localized customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community — spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. "South Korea is a global innovation hub, and by establishing a dedicated team in Seoul, we are investing in the future of multi-omics discovery," said Justin Lee, Vice President, Novogene Asia Pacific, Middle East & Africa (AMEA). "With the launch of Novogene Korea, we are even better positioned to support our customers with rapid, cost-effective, and reliable services that are already trusted by more than 7,300 organizations worldwide. We sincerely thank the Korean scientific community for their continued trust and collaboration in advancing the frontiers of science." Backed by robust government R&D support, world-class academic institutions, and a dynamic biotech ecosystem, South Korea is uniquely positioned to lead the next wave of genomic innovation. Novogene Korea will partner closely with universities, start-ups, and research hospitals to help unlock transformative insights in health, agriculture, and beyond. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Hamilton Spectator
11-06-2025
- Hamilton Spectator
Hamilton walk raises voices against violence
Dozens of bright red heels marched across the city hall forecourt Wednesday, as community members gathered for YWCA Hamilton's Walk a Mile in Their Shoes — a symbolic stride toward ending gender-based violence. Justin Lee of the Hamilton police tries a pair of high heels on for size. Now in its 16th year, the annual walk raised both awareness and critical funds for programs supporting women, children and gender-diverse survivors of violence. Organizers say more than $1.5 million has been raised since the event began in 2009. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Korea Herald
05-06-2025
- Business
- Korea Herald
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink ® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink ® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink ® Reveal. Olink ® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink ® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink ® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink ® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink ® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink ® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Yahoo
05-06-2025
- Business
- Yahoo
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink® Reveal. Olink® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About NovogeneNovogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation. CONTACT: Novogene AMEA (APAC, Middle-East & Africa)marketing_amea@ View original content: SOURCE Novogene
Yahoo
12-05-2025
- Business
- Yahoo
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, LA. The company's presentations include one oral session and two poster presentations that highlight recent scientific advances and underscore the therapeutic potential of Siren's AAV-based immuno-gene therapy platform across solid tumor indications. Presentation details: Oral Presentation: SRN-101 Universal AAV Gene Therapy for Solid Tumors. Dr. Nicole K. Paulk, CEO, Founder, President, Siren Biotechnology May 17, 2025 | 8:00am CST Poster Presentations: Vectorized Interferons Provide a Robust and Sustained Transcriptional Response Over Traditional Non-Vectorized Recombinant Cytokine Therapies in Human High-Grade Glioma Cells. Justin Lee, BS, Preclinical Associate Scientist May 14, 2025 | 5:30 – 7:00pm CST Identification of Pharmacologically Relevant Species for IND-Enabling Toxicology Studies by Deep Comparative Transcriptomic Profiling of PBMCs Treated with Recombinant Human Payloads. Christopher Lovejoy, MS, Preclinical Associate Scientist May 14, 2025 |5:30 – 7:00pm CST 'We're excited to share our latest data with the scientific community at ASGCT, which remains the most prestigious venue for showcasing gene therapy innovations,' said Dr. Nicole K. Paulk, PhD, Siren Biotechnology's CEO and Founder. 'These presentations reflect our continued progress advancing our Universal AAV Immuno-Gene Therapy Platform and our commitment to developing transformative therapies to treat solid tumor cancers.' About Siren Biotechnology Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer. To learn more, visit and follow us on LinkedIn, Twitter, Facebook and Instagram. Universal AAV Immuno-Gene Therapy for Cancer. It's Here. CONTACT: Contact Akela Kuwahara press@
